Avantax Planning Partners’s Amedisys AMED Stock Holding History

Avantax Planning Partners’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-94	Closed	-$6K	–	293
2018 Q1	$6K	Buy	+94	New	+$5.35K	﹤0.01%	1242

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Avantax Planning Partners's AMED Position: Q2 2018 in Review

Avantax Planning Partners sold out of Amedisys (AMED) in Q2 2018, closing a stake of 94 shares — an estimated $6K sold.

Avantax Planning Partners first reported a position in AMED in Q1 2018 and held it in 1 quarter. The position peaked at $6K in Q1 2018. 216 funds tracked by Wall St. Rank hold AMED as of Q2 2018.

Avantax Planning Partners reported no remaining Amedisys position as of Q2 2018 after selling out during the quarter.
Avantax Planning Partners sold 94 Amedisys shares in Q2 2018, an estimated $6K.
Avantax Planning Partners first reported a position in Amedisys in Q1 2018 and held it in 1 quarter.
Avantax Planning Partners's Amedisys position peaked at $6K in Q1 2018.
216 funds tracked by Wall St. Rank held Amedisys as of Q2 2018.

Based on Avantax Planning Partners's 13F filing for Q2 2018, filed 13 Aug 2018.